FADS2 and cancer: Given the capability of n−3 fatty acids to compete with n−6 fatty acids for metabolism, thereby reducing AA-derived eicosanoids and their anti-cancer properties, the supplementation of n−3 fatty acids together with the use of D6D inhibitors might not only make D6D inhibition safer, but also enhance its anti-cancer efficacy.